Amarillo Biosciences, Inc. (AMAR) is a specialty biopharmaceutical company dedicated to the development and commercialization of interferon alpha as a human and animal therapeutic.  AMAR presently owns or licenses 9 patents, and has four pending patents related to the low-dose oral delivery of interferon. AMAR also owns one issued patent concerning Maxisal®, a dietary supplement for the relief of dry mouth.  The Company has completed over 100 studies in humans and animals.  AMAR’s low-dose oral technology reduces or eliminates side effects associated with high-dose injectable interferon.

The Company will focus on regulatory approval and global commercialization of low-dose oral interferon treatment of influenza, a potential multi-billion dollar market opportunity.  AMAR is also working toward FDA approval of oral interferon as treatment of chronic cough in COPD patients and for prevention of relapse in patients with chronic active hepatitis C virus infection.

AMAR stock is publicly traded in the United States in the OTCBB market under the symbol: AMAR.OB.  In Germany, the Company stock is publicly traded on the Frankfurt, Stuttgart, Berlin-Bremen and Xetra exchanges as FZX WKN 917640.

If you need additional Information

                                                            ……………………………..